In vivo benzodiazepine receptor equilibrium dissociation constant, KD, and maximum number of bind ing sites, Bmax, were measured by single photon emission computerized tomography (SPECT) in three baboons. Animals were injected with a bolus followed by a con stant i. v. infusion of the high affinity benzodiazepine ligand [12 3 I]iomazenil. Plasma steady-state concentration and receptor-ligand equilibrium were reached within 2 and 3 h, respectively, and were sustained for the duration (4-9 h) of the experiments (n = 15). At the end of the experiments, a receptor saturating dose of flumazenil (0.2 mg/kg) was injected to measure nondisplaceable activity. Experiments were carried out at various levels of specific
Single photon emission computerized tomogra phy (SPECT) has been traditionally considered a semiquantitative technique, allowing visualization but not quantification of neuroreceptors . Data anal ysis has generally been restricted to empirical meth ods such as region of interest (ROI) counts ratio or ROI washout rates. As these empirical methods do not control for factors such as peripheral clearance, activity, and Scatchard analysis was performed for deri vation of the KD (0.59 ± 0.09 nM) and Bmax (from 126 nM in the occipital region to 68 nM in the striatum). Two animals were killed and [125I]iomazenil Bmax and KD were measured at 22 and 37°C on occipital homogenate mem branes. In vitro values of Bmax (114 ± 33 nM) and 37°C KD (0.66 ± 0.16 nM) were in good agreement with in vivo values measured by SPECT. This study demonstrates that SPECT can be used to quantify central neurorecep tors density and affinity. Key Words: SPECT Benzodiazepine receptors-Equilibrium-Steady state e2 3 I]iomazenil.
binding to plasma proteins, cerebral blood flow, and regional nonspecific binding, the ability of these measures to provide information about receptor density and affinity is questionable .
To test the ability of SPECT to provide quantita tive information about the density and affinity of central neuroreceptors, we perfo rmed SPECT ex periments with e 2 3I]iomazenil, a probe for the cen tral benzodiazepine receptor (Beer et aI ., 1990;  In nis et aI ., 1991a), in three baboons (Papio anubis). In the companion article published in this issue (Laroelle et al . 1994) , we described the derivation of benzodiazepine receptor binding potential (BP), i.e., Bmax/Kn, (Mintun et aI ., 1984) by compartmen tal kinetic analysis of e 2 3 I]iomazenil brain uptake after single bolus injection in three baboons. In the' absence of any information about nonspecific bind ing (10-20% of total binding) , only the total distri bution volume, VT , could be reliably derived by ki-netic analysis. Furthermore, lengthy experiments were needed to derive stable outcome measures (300 min in baboons, 120 min in humans).
Because of the problems associated with kinetic analysis of single bolus experiments, we imple mented an alternative paradigm based on constant infusion of the radiotracer. This paradigm creates and maintains a prolonged state of equilibrium at the level of the receptors, allowing direct measure merit of VT (Frey et aI., 1985; Kawai et aI ., 1991; Carson et aI ., 1992) . Injection of receptor saturating doses of a cold competitor allows for measurement of the equilibrium volume of distribution of nonspe cific binding during the same experiment.
We previously reported determination of in vivo occipital benzodiazepine receptor Bmax and KD in one animal using infusion of high and low specific activity (SA) e 2 3I]iomazenil (Laruelle et aI ., 1993a) .
In the studies reported here, we extended this ap proach to various brain regions and performed these experiments in the three animals previously studied using kinetic analysis of single bolus exper iments. In addition, we performed studies at five levels of receptor occupancy to confirm the as sumption of linearity of the Scatchard plot used to analyze the data. Cerebrospinal fluid (CSF) mea surement of e 2 3I]iomazenil was obtained in one an imal to validate the assumption that, under pro longed plasma and brain steady state, the intrace rebral free tracer equilibrates with the plasma free tracer. Intracerebral radiometabolites were mea sured after prolonged exposure of the brain to high levels of peripheral radiometabolites. At the end of these experiments, two of the three baboons were killed. In vitro Bmax, KD, and molec ular association and dissociation rate constants (ko n and k O ff' respectively) were compared with their in vivo values as derived by SPECT experiments .
METHODS

Radiolabeling
[12 3 1]iomazenil and [1251] iomazenil were labeled as pre viously described (Zea-Ponce et aI., 1993) . As the con struction of the Scatchard plots required an exact knowl edge of SA, [12 3 1]iomazenil preparations were obtained at the desired SA, from high (2,000 Ci/mmol) to low (16 Cilmmol) SA, by adding unlabeled iomazenil. For [1251] _ iomazenil, SA was estimated by ultraviolet (UV) detec tion at 1,087 Ci/mmol on the day of the labeling. The same batch was used in all in vitro experiments reported here. For both in vivo and in vitro experiments, SA was decay corrected for time of injection or day of experiment, re spectively.
SPECT protocol
SPECT scanning experiments (n = 14) were performed in three female baboons (Papio anubis), weighing 10-12 J Cereb Blood Flow Metab, Vol. 14, No. 3, 1994 kg, according to protocols approved by the local animal care committee. Identification numbers of each baboon (l, 2, and 3) were the same as those used in the compan ion paper. At the end of these studies, baboons 2 and 3 were killed. Brains were removed and dissected immedi ately. Tissue samples were frozen within 120 min of death.
Animal preparation, isoflurane anesthesia, and arterial sampling procedures were identical to those described in the companion paper. Radiotracer was administered as a bolus (30 s), immediately followed by a constant infusion for the entire duration of the experiments. Constant infu sion was accomplished through a computer-controlled pump (lMED pump, Jemini PC-I, San Diego, CA, U.S.A.). Experiments lasted 240-540 min, with an aver age duration of 410 ± 102 min (with these and subsequent values expressed as mean ± SD); duration varied accord ing to estimated time needed to reach equilibrium, which was significantly longer when using a tracer infusion of high as opposed to low SA.
Two experiments at high (2,000 Cilmmol) SA and one experiment at low (16 Ci/mmol) SA were performed on each animal. In addition, experiments at 77 Cilmmol (n = 1), 47 Cilmmol (n = 1), and 25 Ci/mmol (n = 3) were performed on baboon 1.
A verage bolus activity was 2.59 ± 0.67 mCL Average rate of infusion was 0.59 ± 0. 19 mCi/h. Average bolus to hourly infusion ratio, B/I, was 4.63 ± 1.56 h. For high (2,000 Ci/mmol) SA experiments (n = 6), the optimal B/I ratio was calculated by computer simulations for each animal, based on the parameters of the peripheral clear ance and the brain rate constants derived from single bo Ius experiment (see Laruelle et aI., 1994) . Average B/I ratios for high SA experiments were 5.81 ± 1. 05 h. Lower B/I ratios were used for low SA experiments (3.75 ± 1.27 h, n = 8). Total injected activity, decay-corrected for the beginning of the experiment, was 6.6 ± 1.8 mCi. A re ceptor-saturating dose of flu maze nil (0.2 mg/kg) was in jected as an i. v. bolus 45 min before the end of the infu sion to measure the equilibrium nondisplaceable activity. Arterial samples were analyzed as previously described (Zoghbi et aI., 1992) .
Data were acquired with the CERASPECT camera (Digital Scintigraphics, Cambridge, MA, U.S.A.) (Hol man et aI., 1990) in continuous mode for 3 min throughout the experiments. Images were reconstructed as described (Laruelle et aI., 1994) . Activity concentrations were transformed in nM using the SA at the time of the begin ning of the experiments.
Analysis of in vivo data
The time activity curve of the arterial free parent com pound, f I Ca(t), was fitted to 3 3 ilCaCt) = 2: Co;e-).. ;/ + CSS 2: foPe-).. ;/) (1) where Ca(t) is the arterial concentration of the parent compound (nM),f 1 is the free fraction of the tracer in the plasma, Co is the zero-time intercept of each e�ponential (nM), Ai is' the elimination rate constant associated with each exponential (min -I ), fo is the fraction of zero-time intercept associated with each exponential, and Css ( oM)
is the free concentration at steady state. The first term of Eq. 1 represents the activity due to the bolus and the second term the activity due to the constant infusion. Css is related to the clearance, C v (Llh) , and the rate of infusion, Ro, (nmol/h), by
(2) From Eq. 1, it is apparent that, in the absence of bolus (Co = 0), the time to reach steady state is determined by the smallest exponent (A 3 ), i.e. the terminal half-life (In(2)/A 3 , 120 ± 39 min, see Laruelle et al., 1994) . Ninety percent of Css is reached after 3.3 half lives (3.3 x 120 min = 396 min). This time can be reduced if a bolus injection is given just prior to the beginning of the constant infusion.
A three-compartment configuration was used to ana lyze these experiments. This model includes the arterial compartment concentration, Ca, the intracerebral nondis placeable compartment concentration, C2, in which the tracer can be free or nonspecifically bound, and the spe cifically bound compartment concentration, C3.
The equilibrium volume of distribution, Vi' (ml/g), of a compartment i was defined as the ratio of the tracer con centration in this compartment to the free tracer in the arterial plasma at equilibrium (Vi = C/f I Ca) (Carson et al., 1992) . VT is the tissue equilibrium volume of distri bution, equal to the sum of V 2 and V 3 , the equilibrium volumes of distribution of the nondisplaceable and recep tor compartments, respectively.
When equilibrium is reached at the level of the recep tors, the Michaelis-Menten receptor-ligand equilibrium equation 
The contribution of the activity present in the vascula ture in an ROI was estimated assuming a blood volume equal to 5% of the ROI volume (Mintun et al., 1984) and subtracted from the activity concentration in the ROI at time t, CROI(t), prior to analysis. Thus, CROI(t) is given by (5) and (6) At equilibrium, VT was directly obtained by the ratio of the brain activity (average value of the last 60 min before flumazenil injection) to the plasma free activity (average plasma activity measured during the same period). V 2 was obtained by the ratio of nondisplaceable activity (activity remaining after flumazenil injection, measured from 2� 40 min postinjection) to plasma free activity at that time. BP, as derived with the equilibrium method, BPe, was calculated as the difference between VT and V 2 • High SA constant infusion experiments were also analyzed with a kinetic three-compartment modeling (Mintun et al., 1984; Logan et al., 1987; Frost et al., 1989; Koeppe et al., 1991) The BP derived by kinetic analysis, BPk, was calculated from kinetic parameters according to (7) where K I and k 2 describe the transfer of tracer across the blood brain barrier and k 3 and k4 the association and dis sociations, respectively, of the tracer-receptor complex.
For derivation of Bmax and KD, data from high and low SA experiments were analyzed by Scatchard transforma tion (Scatchard, 1949) by plotting
Bound
Bmax Bound (8) free
The linear regression of this plot gave the Bmax (x-axis intercept), the BP (y-axis intercept), and the KD (negative inverse of the slope). Ko and Bmax were expressed as nM.
Ex vivo experiment
Baboon 2 was killed by phenobarbital overdose after 500 min of constant infusion (2.17 mCilh, SA = 2,000 Ci/mmol) preceded by a bolus of 9.2 mCi. Before killing, arterial blood (1 ml), venous blood (2 ml), CSF (6.6 ml), and urine (50 ml) samples were obtained. Fluid samples were analyzed for metabolites as described for plasma samples (see Laruelle et al., 1994) . For tissue samples (occipital cortex, striatum, white matter, and cerebel lum), 0.2-0.5 g of tissue was homogenized with 2.5 ml 0.9% NaCI while cooling on ice (Brinkmann Polytron, setting 7, 30 s). A I-ml aliquot of the suspension (contain ing 2, 00�150,000 cpm) was extracted with 3 x 1 ml ethyl acetate and the extract analyzed by HPLC as described for plasma. To correct for recovery of the tracer from the sample matrix, an excess (10 jJ.l, 700,000 cpm) of [12 3 1] _ iomazenil was added to a second aliquot of suspension and the mixture analyzed in the same way. Control ex traction data were used to correct the experimental sam ple extraction, as previously described (Zoghbi et al., 1992) . CSF and plasma samples were analyzed for pro tein-bound radioactivity and concentration of free parent compound, as described for plasma samples (see Laruelle et al., 1994) . Additional brain samples were collected and frozen at -70°C for homogenate binding studies.
In vitro binding studies
In vitro assays were performed on occipital samples obtained from baboons 2 and 3 and from one additional animal (baboon 4), whose brain was obtained under con ditions similar to the others. In vitro assays were per formed at least 60 days after killing in order, to allow complete decay of [1 23 1]iomazenil. On the day of the as say, brain samples were weighed, thawed, and homoge nized with a Polytron (setting 6 for 10 s) in 11400 (wt/vol) wet weight (in mg)/vol (in ml) of buffer (25 mM KP04, 150 mM NaCI, pH 7.4). After homogenization, tissues were centrifuged (20,000g, 4°C, 10 min). Supernatant was dis carded and pellets resuspended and recentrifuged. This procedure was repeated twice.
Incubation was initiated by the successive addition Qf 100 jJ.l of [1 2 5Iliomazenil, 100 jJ.l buffer or unlabeled iom azenil, and 800 jJ.l of tissue solution. A final tissue dilution of 112,400 (wtlvol) was selected so that total binding was between 5 and 10% of total ligand concentration. Incuba-tion was terminated by rapid filtration though GF/B filters on a 48-channel Cell Harvester (Brandel, Gaithersburg, MD, U.S.A.). Filters were washed rapidly three times with 5 ml ice-cold buffer and counted in a COBRA 5010 gamma counter (Packard, Meriden, CT, U.S.A.) with an efficiency of 80%.
Saturation experiments (n = 5-6) were performed by the isotopic dilution method ("cold" saturation) at 22 and 37°C on baboons 2, 3, and 4, using a single concentration of [! 2 5I]iomazenil (0.02 nM) and fifteen concentrations of nonradioactive iomazenil (10-1 4 _10-6 M). Incubation time was 45 min at 22°C and 30 min at 37°C. Each con centration was performed in triplicate. Kinetic experiments were performed on baboon 2. As sociation experiments (n = 3) were performed at 22 and 37°C at four and three [1 2 5Iliomazenil concentrations, re spectively, for 12 time periods ranging from 1 to 90 min. Nonspecific binding was measured as the binding remain ing in the presence of 1 IJ-M iomazenil at 4, 20, and 40 min. Dissociation experiments (n = 3) were performed after preincubation of tissue with 0.02 nM [1 2 5I]iomazenil for 45 min at 22°C and 30 min at 37°C. Dissociation was ini tiated by the addition of I IJ-M iomazenil and terminated at 14 different times ranging from 1 to 120 min. Nonspecific binding was measured with 1 IJ-M iomazenil added at the beginning of the preincubation.
Analysis of in vitro data
Saturation experiments were analyzed by nonlinear re gression analysis using the program LIGAND (Munson and Rodbard, 1980; NIH, Bethesda, MD, U.S.A.). A measurement variance increasing as the square of the val ues was assumed and the least-square criterion adjusted accordingly. Nonspecific binding was estimated by the regression. KD and Bmax values were expressed (nM).
Association and dissociation experiments were ana lyzed using the program Kaleidagraph 2.1 (Abelbeck Software, Reading, PA, U.S.A.). For association exper iments, nonspecific binding at each time was estimated by linear regression of the three measured nonspecific bind ing and this value was subtracted from each point to de rive the specific binding association curve. This curve was fitted by nonlinear regression to the exponential curve Bt = BE(1 -exp(kobst), where Bt is the specific binding at time t, BE the specific binding at equilibrium, and k bs is the observed association rate constant (min -!\ Specific binding dissociation curves were fit to Bt = BEexp(kotyf) after subtraction of the nonspecific binding.
Two methods were used to drive kon and KD. In the first method (ratio method), kon was calculated for each association curve as
with koff equal to the mean koff of all dissociation exper iments performed under similar conditions. In the second (graphical method), values of kobs derived from all asso ciation experiments were plotted against values of the free. Values of koff and kon were then calculated by linear regression according to
In vitro kon and koff values were compared to regional in vivo kon and koff values derived from the rate constants k3 (k3 = konBmaxlV 2 ) and k4 (k4 = koff)' For the purpose of this derivation, we used average regional V 2 and Bmax values measured by equilibrium analysis of constant in fusion experiments and average regional rates constant k3 and k4 measured by kinetic analysis of single bolus ex periments as described (Table 3 of Laruelle et at., 1994) .
Statistical analysis
Data variance was tested for statistical significance with general linear modeling analysis of variance (ANOV A). Particular configuration of ANOV A models are indicated in the results section (dependent variable: ANOV A, factor x factor; p values) with exact p values provided unless p < 0.01.
RESULTS
Peripheral clearance and plasma steady state
Plasma-free iomazenil concentration, metabolite corrected, was essentially stabilized at � 120 min and remained constant for the duration of the ex periments ( Fig. 1) . In contrast, total plasma activity increased with time, reflecting the increasing amount of radiolabeled metabolites.
Clearance and Css were calculated by fitting the arterial free parent compound concentration to Eq. 1 ( Table 1 ). The clearance calculated by the ratio of free concentration at time of measurement (oM) to the infusion rate in nmol/h, Eq. 2, was 34. 4 ± 19 Llh , a value very close to the clearance derived fr om the fit (35.6 ± 17 Llh). As observed in single bolus experiments (see Laruelle et ai ., 1994, Table  2 ), the clearance of baboon 1 (45.9 ± 17 Llh, n = 8) was significantly faster than those of baboons 2 (19.5 ± 2. 11 Llh, n = 3) and 3 (24.0 ± 3. 6 Llh, n = 3) (ANOV A, p = 0. 025). High SA experiments Regional brain [1 2 3I]iomazenil concentration dis played stable levels within 180 min and until the injection of flumazenil, indicating that a state of equilibrium was reached and maintained ( Fig. 2) . Average ROI concentrations for each hour postin jection were calculated for the high SA experiments (n = 6) and expressed as % of the activity during the 60 min preceding the flu maze nil injection ( Table  2 ) . The flumazenil injection induced a rapid dis placement (within 30 min) of the brain activity (Fig.  2) . The average e 2 3 I]iomazenil concentration be tween 20 and 40 min after flumazenil injection rep resented only 10-14% of the concentration prior to injection (Table 2) .
Since stable levels of [1 2 3I]iomazenil concentra tion were observed in both the brain and the arterial plasma during the 60 min prior to flumazenil injec tion, this period was selected for measurement of V T' As brain concentration was stable from 20-40 min post flumazenil injection, this period was se lected to calculate V 2 • The rank order of average regional values of BPe (occipital, 238 ± 5; temporal , 164 ± 6; frontal, 150 ± 3; thalamus, 113 ± 11; stri atum, 107 ± 11) ( Table 3 ) was in accordance with the distribution of benzodiazepine receptors as measured by autoradiography in primate brain (Sybirska et aI., 1992) . Differences in VT , Vl> and BPe between regions and baboons were investi gated by ANOV A. No statistically significant dif ferences between baboons were noted. Regional differences were significant for VT (ANOVA; re gion x baboon; region, p < 0.01; baboon, p = 0.55) but not for V 2 (ANOVA; region x baboon; region, p = 0.28; baboon, p = 0.64) .
Three-compartment kinetic analysis was also per formed on these data (Table 4 ). Since a measured V 2 value was available for each region, the K/k 2 ratio was constrained to V:J ' I ' K I ranged from 0.644 ± 0.202 ml g -I min -I (striatum) to 1.057 ± 0.339 ml g -I min -I (occipital) , with high %CV (from 7 ± 4% in occipital to 27 ± 16% in frontal) . Values of k 3 (from 0.386 ± 0.281 min -I in occipital to 0.122 ± 0. 117 min -I in striatum) and k4 (from 0.0227 ± 0.074 min -I in fr ontal to 0.063 1 ± 0.0246 min -I in thalamus) were affected by a high %CV (49-121% for k 3 ' 49-64% for k4) and poorly identified. The kinetic BP (BPk), derived from the ratio of these rate constants (Eq. 7) , was very close to the BPe measured in each region ( Table 3 ). The average ab solute difference between BPe and BPk, expressed as % BPe, was 4.8 ± 3.6%.
The reproducibility of each outcome measure (VT , V 2 , BPe, and BPk) was evaluated by the %CV between the test and retest ( Table 5 ). The overall %CV (all regions) was 9 ± 1 % for V T' 19 ± 11 % for V 2 ,8 ± 2% for BPe, and 5 ± 2% for BPk. Differ ences in outcome measure reproducibility between regions and animals were investigated by ANOV A. Reproducibility of the V 2 measurement was signifi cantly worse than other outcome measures (p < 0.0 1). There were no significant differences in re producibility between regions (p = 0.40). Baboon 2 test/retest (47 days) had a significantly lower repro ducibility (mean %CV of all outcome measures and all areas 15 ± 14%, n = 20) than did baboons 1 (21 days; 9 ± 7%) and 3 (13 days; 7 ± 5%, p = 0.021).
Low SA experiments
At low SA, brain activIty stabilized within the first hour. VT , V 2 , and B/F were calculated as for high SA experiments. At the lowest specific activity (16 Ci/mmol) , V 2 represented 22 (occipital) to 26% (striatum) of VT• Bmax and KD were derived by Scatchard analysis (Fig. 3 , Table 5 ). Bmax values were significantly different among regions (ANOYA; p < 0.01) but not KD values (p = 0.70). The mean regional KD was 0.59 ± 0.09 nM (n = 15). The coefficient of determination of the regression (r) was higher for baboons 2 (average regional r, 0.96 ± 0.02) and 3 (0.96 ± 0.04) than for baboon 1 (0.85 ± 0.04; ANOY A, p < 0.01), the difference presumably being related to the higher number of points (n = 8) in baboon 1, as compared to baboons 2 and 3 (n = 3). Saturation data from baboon 1 were also analyzed with the nonlinear regression pro gram LIGAND (Munson and Rodbard, 1980) . The one-site model provided results similar to those of linear regression analysis of Scatchard plots. A two site model failed to converge .
Ex vivo experiment
After 500 min of e 23 I]iomazenil infusion, radiola beled metabolites were present at negligible levels in gray matter ( < 1 % of activity) ( Table 6) and at low levels in white matter (15%) and CSF (24%). In con trast , radiolabeled metabolites represented 71 and 74% of total activity in arterial and venous plasma, respectively; 100% of the urine activity consisted of radiometabolites.
In CSF, the parent compound was essentially free (free fraction = 0.927). Free CSF parent com pound concentration (0. 046 nM) was similar to Values are means ± SD of six experiments. Parameters were estimated by three compartment fit with K/k2 ratio constrained to V2! 1 ' with! l measured in plasma and V2 measured after flumazenil injection . CV% was calcuiated as 100 (standard error of the parameter as estimated by diagonal of covariance matrix/parameter value).
those of free parent compound in arterial and ve nous plasma (0.055 and 0.045 nM, respectively, Ta ble 7).
In vitro experiments
Saturation experiments. Saturation experiments were performed on the occipital cortices of baboons 2,3, and 4 at 22 and 37°C (Table 8, Fig. 4 ). The Ko at 22°C (0.35 ± 0.11 nM, n = 16) was significantly lower than the Ko at 37°C (0.66 ± 0.16 nM, n = 6; ANOV A, p < 0.01), but the Bmax was similar at 22 (113 ± 35 nM, n = 16) and 37°C (116 ± 26 nM, n = 6; ANOV A, p = 0.83). No significant differences in Ko or Bmax values were found between the three animals (Ko: ANOVA, p = 0.53; Bmax: ANOVA, p = 0.65). The mean Bmax derived from all assays (n = 22) was 114 ± 33 nM. This value compared fa vorably to the mean Bmax derived from the in vivo experiments (126 ± 13, n = 3). Of interest is the finding of a lower Bmax for baboon 2 as compared to baboon 3 both in vitro (108 ± 20 versus 124 ± 30 nM) and in vivo (129 versus 137 nM). The Ko de rived from SPECT experiments (0.54 ± 0.04, n = 3) was somewhat closer to the in vitro Ko measured at 37°C (0.66 ± 0.16 nM) than to that measured at 22°C (0.35 ± 0.11 nM). A limited number of saturation studies (n = 2) were performed to measure Bmax in four additional regions (baboon 2: temporal cortex, Results of the ratio (Table 9 ) and graphical ( Fig. 5) analyses were i� good agree ment. The dissociation was about ten times slower at 22°C, (koff = 0.0301 ± 0.0021 min -I , n = 3, corresponding to a dissociation half time, Td 0.5, of 22.3 min) , than at 37°C (koff = 0.320 ± 0.006 min -I, n = 3, Td 0. 5 of 2.3 min; ANOV A, p < 0.01). The association was about four times slower at 22°C (kon = 0.124 ± 0.058 min -I nM -1, n = 3), than at 37°C (kon = 0.364 ± 0.420 min -I nM -1; ANOV A, p < 0.01). Ko values calculated fr om kinetic experi ments (0.29 ± 0.11 nM at 22°C and 0.84 ± 0.11 nM at 37°C) were in excellent agreement with Ko values derived from saturation experiments.
In vivo koff and kon values were calculated using the regional in vivo Bmax values derived from con stant infusion experiments and the regional k 3 and k4 values derived from kinetic analysis of single bo lus experiments, where rate constants were best identified ( Table 3 , Model B). The in vivo Ko value derived from the in vivo korr/kon ratio (0.62 ± 0.09) was in excellent agreement with that derived by Scatchard analysis (0.59 ± 0.09 nM). However, as sociation and dissociation rate constants observed in vivo were significantly slower than those in vitro. Furthermore , in vivo kolT values measured at low receptor occupancy were not compatible with the rapid rate of brain washout observed after injection of receptor-saturating doses of flumazenil. For ex ample , in the experiment depicted in Fig. 6, 80% of the tracer washed out with a rate of 0.18 min -I . Given the fact that the delivery and binding of flu mazenil is rapid but not instantaneous, this obser vation suggested that koff should be >0.18 min -I, which is compatible with the 37°C in vitro koff (0.32 min -I) value but not with the in vivo koff value calculated in the absence of flumazenil (0.015 min -I).
DISCUSSION
The most significant results of these studies are those demonstrating the fe asibility of a constant in fu sion paradigm to induce and sustain a state of equilibrium at the receptor site, and the excellent agreement between in vivo BP values derived by kinetic and equilibrium methods and between m vivo and in vitro measurement of Bmax and Ko.
Advantages of the constant infusion paradigm
Multiple advantages are associated with this con stant infusion paradigm: can be calculated independently of the transfer rate constants that are difficult to identify unless some assumptions and/or constraints are implemented in the regression process (see Laruelle et ai ., 1994) . Furthermore , the kinetic model becomes nonlinear and, therefore , more complex at nonnegligible re ceptor occupancy . That is not the case for the con stant infusion/equilibrium paradigm. This paradigm provides a stable baseline for evalu ation of pharmacological challenge tests or dose receptor occupancy relationship studies (Innis et ai ., 1991b) . In addition, this stable baseline allows the direct measurement of the nondisplaceable compartment equilibrium distribution volume (V 2 ) after flu maze nil injection. The estimation of V 2 is problematic in the absence of a region of reference devoid of receptors . In Laruelle et ai ., 1994 we re ported that the estimation of V 2 by an unconstrained three-compartment model was associated with a relatively large error. This induced a lower repro ducibility of the BP estimation by the unconstrained three-compartment fit (% CV, mean of all regions = 15%) as compared to a V 2 constrained fit (% CV, mean of all regions = 10%). The direct measure ment of V 2 in each region in the studies reported here contributed to an increased reproducibility (% CV, mean of all regions: 8 ± 2%).
(c) Direct measurement of the free tracer concen tration. This paradigm avoids the assumptions needed for equilibrium analysis of bolus-only exper iments regarding the level of free tracer in the brain at equilibrium. In the equilibrium method devel oped by Farde et ai . (1986) for analysis of [llC]ra clopride binding, the total cerebellar activity is used as an estimate of the free (V 2 is assumed to be unity) . As acknowledged by the authors (Farde et aI ., 1989) , this assumption is likely to produce an artifactual 10-fold increase of the Ko . Using a con stant infusion paradigm, the concentration of free tracer in the brain can be directly estimated by the measurement of free tracer in the blood. The valid ity of this approach has been confirmed by CSF and microdialysis measurements. Using CSF tracer concentration as a measure of the free intracerebral tracer concentration, Kawai et ai. (199 1) found a close correlation between CSF and plasma water tracer concentration under constant infusion. Using microdialysis, Dubey et ai. (1989) showed that the ratio between intracerebral free concentration of eH]diazepam and free plasma concentration was equal to unity at equilibrium. In this study, we ob- tained one CSF sample during [1 2 3I]iomazenil con stant infusion and found a concentration similar to arterial and venous free tracer concentrations, sup porting the validity of this approach for e 2 3 I]ioma zenii.
(d) Insensitivity to the ratio of peripheral clear ance and brain-washout rate. The method devel oped here is similar to the "transient equilibrium" analysis method used to measure e'C]flumazenil BP (Pappata et aI., 1988; Brouillet et aI ., 1990 ; Iyo et aI ., 1991) , with the exception that, through the constant infusion, the terminal half life is effectively set to zero. Transient equilibrium analysis method measures the regional volume of distribution when the brain to plasma ratio is constant, i.e., when both concentrations decrease at the same rate . However, Carson et ai . (1992) recently demonstrated that this ratio (Va) is an overestimation of the true equilib- (nM) 5 0.0301 ± 0.0021 0.124 ± 0.058 0.29 ± 0.11 4 0.320 ± 0.006 0.364 ± 0.053 0.84 ± 0.11 5 0.0249 ± 0.0027 0.0154 ± 0.0013 0.62 ± 0.08
In vitro values were measured on occipital homogenate membranes from baboon 2. In vivo values are average values from five regions, using average in vivo Bmax and average regional k, and k4 as derived from single bolus experiments in baboons 1, 2, and 3.
a Values are mean ± SD.
rium distribution volume by a factor related to the ratio of A.n, the terminal half-life , to <X l ' the smallest eigenvalue of the brain impulse response function, according to the following equation
Hence, during constant infusion, A.n = 0 and the brain/plasma ratio (Va) are true measures of VT .
(e) Insensitivity to blood flow changes during the experiment. Both kinetic and equilibrium analyses of reversible tracers, as opposed to empirical meth ods, provide blood-flow-independent outcome measures. However, kinetic analysis assumes that blood flow is constant over the course of the exper iment. This might not be true, especially in human experiments. In contrast, in the constant infusion paradigm, once plasma steady state and receptor equilibrium have been established, the brain activ ity concentration is independent of the blood flow . [1231]iomazenil washout from the occipital cortex (ba boon 1) after flumazenil injection (0.2 mg/kg). These data were acquired during a constant infusion experiment (2,000 Cilmmol), 420 min after initiation of the constant infusion (0.58 mCi/h). The time on the x-axis is the time after fluma zenil injection. About 80% of the tracer washed out at a rate of 0.18 min -1, wh ich is > 1 0 ti mes faster than the in vivo k Off' as measured in kinetic experiments at high SA (0.0154 min-1). This paradox, observed for multiple high affinity ligands, is only poorly elucidated. of the lower sensitivity of SPECT as compared to positron emission tomography (PET) , the minimal acquisition time needed to reach an adequate level of counts is longer for SPECT, limiting implemen tation of the kinetic method in SPECT experiments. Because the constant infusion method provides a stable level of activity for a prolonged period of time, the acquisition time can be greatly increased, allowing higher counting statistics and resolution, and, as a consequence, lower doses of activity and lower radiation exposure to human subjects.
(g) Short scanning session. In the studies de scribed in this article , data were acquired through out the experiment. However, the equilibrium anal ysis was performed only on data acquired 60 min before flumazenil injection. U sing data acquired only 15 min before flumazenil injection yielded sim ilar results (data not shown) . Thus, in human stud ies, data acquisition can be limited to 15 min as compared to single bolus/kinetic analysis experi ments, in which a minimal 120-min period of acqui sition is needed to derive the BP (unpublished data) .
(h) No arterial sampling. In this method, a lim ited amount of blood sampling is needed to measure the C ss concentration of the tracer, as opposed to the single bolus/kinetic analysis protocol, which re quires characterization of the input function for the whole duration of the experiment. In addition, we can assume that, under steady state conditions, ar terial and venous tracer concentrations would equil ibrate and that no arterial sampling would be needed. This hypothesis will be tested in our exper iments in human subjects.
(i) Simple computation procedure. The ability to derive the paradigm of interest without prior deri vation of rate constants make the computation pro cedure much easier. A pixel-by-pixel analysis would, therefore, be easier to implement.
Problems associated with the constant infusion paradigm
Potential problems associated with the use·of this method must be noted. If the time spent in the cam era can be substantially reduced, the overall dura tion of the experiments (infusion time) is increased by two--three-fold, which is not always convenient. Although infrequent, there is a potential for pump failure. Of bigger concern is the fact that, in a re duced version of the protocol (data acquired only at the end of the experiments), it might be difficult to verify that equilibrium has been reached by the time of data acquisition. Several acquisitions might, thus, be needed to establish that equilibrium has been reached.
In the experiments reported here , we used pe ripheral clearance data obtained in these animals in previous single bolus experiments to optimize the bolus to hourly infusion ratio needed to reach equi librium rapidly. The use of a common, standard bo lus to hourly infusion ratio for each animal would have delayed establishment of the equilibrium in some experiments. In human studies, no a priori knowledge of the clearance would be available. However, preliminary experiments in healthy hu man subjects (n = 8, unpublished data) showed that a bolus to hourly infusion ratio of 3.6 succeeded in establishing equilibrium well within 4 h in all re gions. This is only a concern for high SA experi ments. In low SA experiments, equilibrium is es tablished very rapidly.
Comparison between equilibrium and kinetic analysis
There was excellent agreement between kinetic and equilibrium BP in all regions for the six exper iments performed at high SA, which supported the notion that a state of equilibrium had been reached by the time of measurement of BPe. However, the standard errors associated with k 3 and k4 were high. This was related to the ab sence of a washout phase, providing little information for k4 estimation. As a result, the k 3 /k4 ratio was stable, but not their indi vidual values. Single bolus experiments appear, thus, to be the protocol of choice for individual der ivation of the rate constants.
Derivation of Ko and Bmax
Experiments performed at low SA allowed calcu lation of Ko and Bmax. As expected, Bmax varied across regions (p < 0.05), but not Ko (mean Ko: 0.59 ± 0.09 nM). Relative regional differences in Bmax were linearly correlated with regional differ ences in BP as derived by kinetic analysis of single bolus or constant infusion experiments. Provided that Ko values are not altered by disease state or medication, BP could be used as an index of recep tor density.
In one animal, eight experiments were performed at various levels of SA to test the linearity of the Scatchard plot. Points were randomly distributed around the regression line and a two-site fit did not converge , indicating that [1 2 3 I]iomazenil was bind ing to a homogeneous population of sites. This con firmed the validity of the derivation of Bmax and Ko based on results of two experiments performed at high and low SA, respectively. Additional experi ments are needed to define the optimal level of re ceptor occupancy to be targeted with low SA ex periments. If the measure variance is constant, a high receptor occupancy is desirable from the re gression point of view (Rovati et aI ., 1988) . How ever, reduction of counts and the statistical noise associated with very low SA must be taken into account.
Ex vivo metabolite analysis
During constant infusion experiments, the brain is exposed to high levels of metabolites for a pro longed period. It was, thus, important to verify that, under these conditions, metabolites do not signifi cantly cross the blood-brain barrier. Metabolite levels were negligible in gray matter, indicating that the activity measured in these areas represented only parent compound. 0. 11 nM) . This led to the conclusion that both the association and dissociation processes are mark edly slower in vivo than in vitro . A similar obser vation was reported and discussed for eH]scopo lamine in vivo binding in rodents (Frey et aI ., 1985) . The authors suggested that diffusion barriers and/or competition with endogenous transmitters could ex plain the in vivo-in vitro discrepancy. Since we ob served lower association and dissociation rates in vivo , we would favor the first hypothesis (diffusion barriers) over the second one (endogenous compe tition) .
In vivo receptor-ligand interaction kinetics are complex as revealed by the discrepancy between the off-rate measured at tracer doses and the rapid washout induced by flumazenil injection. Similar observations have been reported with various opi ate (Perry et aI ., 1980; Frost and Wagner, 1984) and dopamine D 2 antagonists (Votaw and Kessler, 1991) . We observed the same phenomenon with the dopamine transporter ligand e 23 I]f3-CIT (Laruelle et aI ., 1993c) .
To explain this phenomenon, Perry et aI . (1980) and Frost and Wagner (1984) postulated the exis tence of a synaptic compartment in which the ligand is trapped by rebinding processes in the presence of available receptors. More formally, these theories propose that the observed dissociation rate (kout) is related to the true molecular dissociation rate (koff) according to
where Bmax' is the density of receptors available for binding. At full receptor occupancy (for example, after flu maze nil injection) , Bmax' = 0 and k o u t = koff' The synaptic compartment theory in this for mulation only partially explains the data reported here . This theory predicts a higher observed k o ff (k ou t) and a lower affinity at high receptor occu pancy as compared to low receptor occupancy. In that case, the Scatchard plot would be curvilinear . However, the Scatchard plot reported here was lin ear, indicating that [1 23 Iliomazenil was bound to a homogenous population of sites with similar affinity at any level of receptor occupancy. Thus, the rela tionship between receptor occupancy and the kinet ics of in vivo ligand-receptor interaction remains to be elucidated.
Conclusion
In conclusion, we demonstrated the fe asibility of measuring receptor parameters Bmax and KD with SPECT, using equilibrium analysis of radiotracer J Cereb Blood Flow Metab. Vol. 14. No. 3. 1994 constant infusion experiments. The accuracy of the determination of BP, KD, and Bmax was confirmed by in vitro binding experiments performed on the same animals. Implementation of this method in hu man subjects is currently under investigation.
